absTRaCT Toll-like receptors (TLRs) In conclusion, TAK-242 does not negatively influence perfusion recovery following hind limb ischemia despite its TLR4 inhibiting properties.
(LPS) following TAK-242 incubation. After stimulation, cellular TLR4 activation was measured using FACS and Tumor Necrosis Factor alpha (TNF-α) release was measured using ELISA. Next, the effect of TAK-242 was tested in a mouse model for arteriogenesis on perfusion recovery. TLR4 responses measured by TNF-α levels were inhibited by TAK-242 in human and mouse blood after long-term stimulation. TAK-242 attenuated TLR4 responses in vivo, but did not inhibit perfusion recovery in mice.
In conclusion, TAK-242 does not negatively influence perfusion recovery following hind limb ischemia despite its TLR4 inhibiting properties. However, arteriogenesis is often inadequate to prevent tissue ischemia in patients suffering from PAD.
Arteriogenesis is characterized as an inflammatory process, in which activation and local tissue infiltration of monocytes and T lymphocytes play an important role. 
MaTeRials and MeThods

Ethics statement
All animal experiments in the present study were approved by the university animal 
Whole blood stimulations
Whole blood from healthy volunteers and C57Bl/6J mice was collected in heparinized tubes. Blood was incubated with TAK-242 (0.3 mg/ml) for 30 minutes, followed by incubation with different LPS concentrations (0-500 ng/ml) at 37 °C. Dosage of TAK-242
was based on earlier studies 15, 16 PBS stimulation served as a control. For CD11b and L-selectin expression, human and mouse whole blood were incubated with LPS in a 96-wells plate for 30 minutes at 37 °C followed by FACS analysis. For TNF-α expression measurements, human whole blood was incubated with LPS for 2 hours at 37 °C and mouse whole blood was incubated overnight (20 hours) at 37 °C. Whole blood was centrifuged at 300x g, for 5 minutes and plasma was stored for TNF-α measurements.
Flow cytometry
LPS stimulation on whole blood was followed by staining with FACS antibodies. The following antibodies were used: CD14 RPE-Cy5 (monocytes, Serotec), CD66b PE (neutrophils, Biolegend), CD11b PE-Cy7 (BD), CD62L ECD (L-selectin, Beckman Coulter). For mouse whole blood, the following antibodies were used: F4/80 Alexa-647 (monocytes, TLR4 inhibitor TAK-242 in perfusion recovery 109 eBioscience), Ly-6G PE (neutrophils, eBioscience), CD11b FITC (Bioconnect) and CD62L PE-Cy7 (Abcam).
Enzyme-linked immunosorbent assay
TNF-α levels in plasma from stimulated whole blood was quantified using sandwich ELISA kits according to manufacturer's instructions (BendermedSystems for human TNF-α; R&D Systems for mouse TNF-α).
Animals, in vivo testing and operation procedures
All procedures were performed on male C57BL/6J mice and started when the ani- For in vivo testing of TAK-242 effects during perfusion recovery, mice received TAK-242 dissolved in PEG-400 (5mg/ml) infused in Alzet osmotic micro-pumps (DURECT corp., model 1007D; delivery rate 0.5 ul/h, 7 days) and primed overnight at 37 °C according to manufacturer's instructions. Delivery rate of TAK-242 was 3.0 mg/kg/ day 15, 16 . Micro-pumps were placed subcutaneous (s.c.) between the scapulae, followed by unilateral double electrocoagulation of both femoral artery and iliac artery.
Perfusion recovery was monitored using Laser-Doppler perfusion imaging (LDPI) (Moor Instruments, Devon, UK). LDPI measurements were performed before and after surgery and were continued until 28 days with intermediate measurements at day 3, 7, 10, 14
and day 21. The surgical procedure has been described in detail previously 17 . Perfusion recovery in the ischemic limb is expressed as a percentage of the contralateral non-ischemic limb perfusion. Blood was collected via a tail vein cut at day 3 and 7 and analyzed for TNF-α levels.
TAK-242 was also tested in vivo via a single i.m. injection in the right adductor muscle followed by unilateral femoral artery ligation. Mice underwent unilateral femoral artery ligation and received follow-up of perfusion recovery using LDPI at day 4 and 7 and were terminated at day 7. The surgical procedure has been described in detail previously 18 . 
Statistical analysis
ResulTs
Ex vivo TAK-242 effects on TLR4-induced cell activation
Heparinized human whole blood from a healthy volunteer and whole blood from a affected CD11b and L-selectin expression at higher LPS concentrations as well ( Figure   1B ). In mice, hardly any inhibitory effect was observed of TLR4 activation by TAK-242 on cell-based activation markers (Figure 2A-B) .
Levels of TNF-α were measured in plasma from heparinized whole blood both from a healthy donor as well as C57BL/6J mice at baseline following LPS stimulation. A dosedependent TNF-α production could be observed after LPS stimulation. Pre-incubation of TAK-242 resulted in dramatic decrease of TNF-α production in human (100% decrease, Figure 3A ) as well as mouse whole blood (88-91% decrease, Figure 3B ). For human blood, TNF-α levels after TAK-242 incubation and subsequent LPS stimulation were below the detection limit.
In vivo TAK-242 effects on perfusion recovery after slow and systemic release
After confirming the TLR4 inhibitory effects of TAK-242 in vitro, we assessed the effect of TAK-242 in vivo. TAK-242 was administered via Alzet micro-pumps for continuous, slow and systemic release subcutaneously in mice followed by unilateral femoral artery ligation. Perfusion recovery was measured over 28 days following surgery. No significant differences in perfusion recovery were observed at all measured time points between TAK-242 treatment and control. All mice showed full recovery after 7 days TLR4 inhibitor TAK-242 in perfusion recovery 111
( Figure 4A ). To test the inhibitory effects of TAK-242 on TLR4 stimulation after micropump administration, whole blood was collected at day 3 and 7 after surgery. At day 3, ex vivo whole blood stimulation with LPS after TAK-242 administration resulted in higher TNF-α levels compared to LPS stimulation only (control mice). However, no statistical significant differences could be observed (LPS 1 ng/ml, p=0.81; LPS 10 ng/ml, p=0.92;
LPS 100 ng/ml, p=0.11). At day 7, TAK-242 administration inhibited TNF-α levels after LPS stimulation, whereas control mice maintained TNF-α levels compared to day 3 (LPS 100 ng/ml; p=0.03) ( Figure 4B ). 
Intramuscular administration of TAK-242 in vivo
Since continuous and slow release of TAK-242 via micro-pumps did not inhibit perfusion recovery after hind limb ischemia. To test whether the route of application was responsible for the observed results, the compound was tested in vivo using intramuscular (i.m.) injection. Control mice received PBS injection. Blood was collected 24 hours after injection and was stimulated for 20 hours with three different concentrations of LPS (0 ng/ml, 125 ng/ml, 500 ng/ml). After i.m. administration, TAK-242 treatment resulted in a 60% to 65% decrease in TNF-α production compared to control (PBS) treatment 24 hours after administration. These differences were not statistically significant (control vs TAK-242; LPS 125 ng/ml, p=0.11; LPS 500 ng/ml, p=0.15) ( Figure 5) . antibody reduced myocardial I/R injury in pigs 5 and was able to provide protection from I/R injury in a model for kidney transplantation in mice 20 . Next to TLR2 inhibitors, also TLR4 inhibitors have been extensively studied in infectious diseases as described earlier with different approaches for administration. In this study, we investigated whether in vivo administration of a TLR4 antagonizing compound would negatively influence perfusion recovery after hind limb ischemia in mice. We hypothesized that systemic in vivo administration of TAK-242 could inhibit perfusion recovery after hind limb ischemia, which could be considered as a negative side effect of TLR4 inhibition.
First, we observed that TAK-242 was able to inhibit TLR4 activation measured as CD11b and L-selectin expression on human monocytes and neutrophils in vitro. However, this effect could not be observed in murine blood cells as was analyzed by FACS.
In contrast, in both human and murine whole blood, inhibition of LPS induced TNF-α production was observed. Previously, it has been demonstrated that TNF-α can exert an accelerating role by positively modulating arteriogenesis in mice and rabbits 18, 21, 22 .
Therefore, measuring TNF-α levels after LPS stimulation is not just reflecting TLR4 activation, but it also reveals increased expression of an inflammatory parameter that can stimulate arteriogenesis. However, one should keep in mind that effects of TAK-242 on human and murine cells are difficult to compare, since TAK-242 metabolites are known to have differences in pharmacokinetics in various species 23 .
TAK-242 has been described extensively as a specific inhibitor of TLR4 signaling in vitro using murine peritoneal macrophages for cytokine read-out after LPS stimulation 24 . Zhou et al also showed that TAK-242 inhibits all downstream effects of TLR4 activation in THP-1 cells, a human monocytic cell line often used for TLR4 signaling research 25 . From these and our research we can state that TAK-242 is biologically active in inhibiting TLR4 responses in both species. Unfortunately, the authors did not mention duration of TAK-242 pre-incubation, since this is crucial for the regulation of CD11b and L-selectin expression, as well as TNF-α production. Also, Takashima et al 14 described
the inhibitory effects of TAK-242 on TLR4 activation in a human monocytic cell line, but it was not described if TAK-242 was incubated prior to or simultaneously with LPS stimulation. Our results may seem contradictory, however, long-term effects of TAK-242 on TLR4 stimulation is reflected by TNF-α release, whereas the changes in CD11b and L-selectin expression can already be normalized due to tolerance induction long after TLR4 stimulation.
TAK-242 was delivered in vivo by systemic release of TAK-242 in osmotic micropumps to achieve systemic TLR4 inhibition in combination with unilateral iliac and femoral artery ligation. However, inhibition of perfusion recovery was absent. This raised the question whether TAK-242 was able to inhibit TLR4 activation in vivo in mice by systemic delivery via osmotic micro-pumps. At day 3, we did not observe an effect of TAK-242 treatment regarding TNF-α responses. Moreover, TAK-242 treatment even led to a higher response in compared to PBS treatment as a result of the placement of osmotic micro-pumps. Therefore, the effect of TAK-242 treatment on TLR4 stimulation was overruled by the subcutaneous pump placement observed on day 3, since control TLR4 inhibitor TAK-242 in perfusion recovery 117 mice did not receive a pump. However, at a later time point (day 7), the TNF-α response in control mice was still high, whereas TAK-242 treatment was able to induce TLR4 inhibition, measured as lower TNF-α levels. Although TLR4 inhibition was eventually achieved by TAK-242, this delayed effect can explain why perfusion recovery was not inhibited compared to the control group. Previously, TNF-α levels have been used as a measure of TLR responsiveness, but we did not study the association between in vivo TNF-α levels and arteriogenesis in this study. Therefore, our results do not contradict the current view that TNF-α release induces arteriogenesis.
Since the subcutaneous delivery of TAK-242 did not affect perfusion recovery, we 
Limitations
In this study, we did not investigate the dose-dependency of TAK-242 in our model for arteriogenesis. This would be useful to assess the optimal effect of TAK-242 on perfusion recovery after hind limb ischemia. Furthermore, the extrapolation of animal models to a human setting merits careful consideration, since there appears to be a wide range of species-dependent variation in the effect of TAK-242. Therefore, the results from this mouse study need to be carefully interpreted, before any conclusions can be drawn regarding the effects of TAK-242 in a clinical setting.
Conclusion
TAK-242 has inhibitory effects on TNF-α production after TLR4 stimulation both in vitro as well as in vivo in mice. However, this inhibition may only exert a short-term effect.
Although TLR4 inhibition as recently been proven to inhibit atherosclerotic lesion de-
